This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PDE4D / 3',5'-cyclic-AMP phosphodiesterase 4D · IHC design guide
Design Immunohistochemistry for PDE4D
Plan PDE4D staining in paraffin sections using the IHC-validated antibody A01111-1 at 0.5–1 μg/ml (datasheet: IHC-P dilution). Compare the cytoplasmic pattern with tissue controls while accounting for uncertain staining reliability (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PDE4D Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining across many cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A01111-1) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining has only medium consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Tissue-enhanced RNA: marrow, muscle (HPA tissue RNA) | |
| Isoform / epitope | 12 isoforms; N-terminal epitopes may vary; no TM span (UniProt) |
Section 1
Recommended PDE4D IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by four published PDE4D IHC protocols covering liver, aorta, rat cortex, and pancreatic tumor sections (PMC12375944; PMC8776755; PMC7655962; PMC6856734).
| Sample | Paraffin-embedded mouse lung tissue; fixative not specified (datasheet A01111-1) |
| Fixation | Image fixative and duration unreported (datasheet A01111-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A01111-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01111-1) |
| Primary antibody | Rabbit anti-PDE4D, 0.5-1μg/ml (datasheet A01111-1) |
| Primary incubation | Overnight at 4 °C (datasheet A01111-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A01111-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PDE4D-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with heat-mediated citrate retrieval at pH 6 (datasheet: A01111-1; PMC6856734); optimize against the sample and detection method.
Section 2
What Is the Expected PDE4D Staining Pattern?
Expect PDE4D mainly in the cytoplasm of many cell types, with possible membrane-associated staining, including the apical membrane of colonic crypt cells (HPA: ubiquitous cytoplasmic expression; UniProt Q08499: subcellular location). Colon glandular cells and heart cardiomyocytes are among the reported high-staining cells (HPA: tissue IHC). Treat intensity and compartment calls cautiously: the tissue IHC profile has uncertain reliability (HPA: tissue IHC). PDE4D has no transmembrane segment (UniProt Q08499: topology).
| Cytoplasmic staining in colon glandular cells, with possible apical accentuation. | This fits the reported high staining of colon glandular cells (HPA: tissue IHC) and PDE4D's cytoplasmic location and apical association in colonic crypt cells (UniProt Q08499: subcellular location). Assess the glandular cells themselves; a stained section alone does not establish that every coloured structure is PDE4D (general IHC practice). |
| Strong staining confined to nuclei, with little cytoplasmic or membrane signal. | A nuclear-only IHC pattern differs from the reported ubiquitous cytoplasmic tissue pattern (HPA: tissue IHC). Nucleoplasm is only an additional, uncertain ICC-IF location (HPA: subcellular). Check the counterstain, detection background and antibody controls before calling the nuclear signal specific (general IHC practice). |
| Signal mainly in cells other than the expected glandular cells in a colon section. | Colon glandular cells are reported as high staining (HPA: tissue IHC). An unexpected cell distribution can reflect off-target antibody binding or endogenous detection activity (general IHC practice); it cannot be assigned to PDE4D solely from colour. Compare cellular morphology and appropriate detection controls (general IHC practice). |
| Weak, diffuse colour across tissue and blank areas, with poor cell boundaries. | A broadly diffuse deposit is difficult to reconcile with a readable cellular pattern (general IHC practice). HPA reports cytoplasmic expression, but its tissue IHC reliability is uncertain (HPA: tissue IHC). Inspect a no-primary control and optimise blocking, washing or detection conditions before scoring (general IHC practice). |
| No signal in colon glandular cells or heart cardiomyocytes. | Both are listed as high-staining cell populations (HPA: tissue IHC), so a blank run warrants a technical check. Verify that tissue is present and interpretable, then review retrieval and detection controls (general IHC practice). Because the HPA tissue IHC profile is uncertain, absence alone does not prove biological loss of PDE4D (HPA: tissue IHC). |
💡Expected PDE4D appearanceCall an IHC result compatible when identifiable high-staining cells, such as colon glandular cells, show clear cytoplasmic signal with possible apical accentuation (HPA: tissue IHC; UniProt Q08499: subcellular location); widespread featureless deposit or nuclear-only colour warrants control review (general IHC practice; HPA: subcellular).
| Cell and tissue choice (HPA: tissue IHC) | Colon, appendix, duodenum, epididymis and fallopian tube glandular cells; cerebellar granular-layer cells; endometrial stromal cells; and cardiomyocytes are listed as high (HPA: tissue IHC). Parathyroid glandular cells, vaginal squamous cells and soft-tissue fibroblasts are listed as low, not negative (HPA: tissue IHC). |
| Location and topology (UniProt Q08499: subcellular location and topology) | PDE4D is reported in cytoplasm, membranes and cytoskeletal compartments, with apical colonic crypt localisation (UniProt Q08499: subcellular location). It has no transmembrane segment (UniProt Q08499: topology); membrane-associated staining therefore need not resemble an integral membrane protein (general interpretation of topology). |
| Strength of the tissue evidence (HPA: tissue IHC and antibody validation) | The tissue profile is described as ubiquitous cytoplasmic expression, but antibody staining has only medium consistency with RNA data and is rated uncertain (HPA: tissue IHC). The listed antibody, HPA045895, has uncertain IHC validation (HPA: antibody validation). Treat a matching pattern as supportive, not definitive. |
| Isoform coverage (UniProt Q08499: isoforms) | UniProt lists 12 PDE4D isoforms (UniProt Q08499: isoforms). Without an epitope assignment for the antibody in the supplied evidence, the observed stain cannot be assigned to a particular isoform or assumed to cover all isoforms. Compare like tissue compartments when interpreting differences (general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected high-staining cells are blank. | A failed retrieval, primary-antibody or detection step is possible (general IHC practice); high staining is reported for colon glandular cells and cardiomyocytes (HPA: tissue IHC). | Run a suitable positive section with the same IHC workflow; check reagent delivery, retrieval conditions and the detection control (general IHC practice). Avoid calling biological absence from a failed control, especially given uncertain tissue IHC reliability (HPA: tissue IHC). |
| Colour spreads through tissue with little cellular definition. | Excess detection deposit, inadequate washing or nonspecific antibody binding can obscure cellular localisation (general IHC practice). | Review a no-primary control, blocking and wash steps; adjust antibody or detection conditions using the catalog IHC-P protocol as the starting point (general IHC practice). Score only a resolved cellular pattern, considering the uncertain HPA IHC profile (HPA: tissue IHC). |
| Nuclear staining dominates the section. | The IHC tissue summary is cytoplasmic (HPA: tissue IHC); nucleoplasm is an uncertain additional ICC-IF location (HPA: subcellular). Nuclear colour alone has limited support. | Compare the counterstain and no-primary control, then seek cytoplasmic staining in an expected cell population before interpreting the result (general IHC practice; HPA: tissue IHC). |
| A low-staining comparison tissue appears negative. | Parathyroid glandular cells, vaginal squamous cells and soft-tissue fibroblasts are described as low, not absent (HPA: tissue IHC). A low signal may be hard to resolve in a particular run (general IHC practice). | Use a reported high-staining cell population to verify the run; record the comparison as below detection if appropriate, rather than asserting PDE4D absence (HPA: tissue IHC; general IHC practice). |
| Unexpected cells stain more strongly than the expected population. | Off-target binding or endogenous detection activity is possible (general IHC practice). The reported HPA levels identify cell populations to compare, but have uncertain tissue IHC reliability (HPA: tissue IHC). | Confirm cell identity by morphology and counterstain; inspect no-primary and detection controls, then repeat under optimised IHC conditions if needed (general IHC practice). |
| IF/ICC shows membrane, cytosolic or nuclear signal: how should it be read? | Plasma membrane is supported; cytosol, nucleoplasm, nuclear membrane and primary cilium are uncertain ICC-IF locations (HPA: subcellular). | Interpret the IF/ICC image using its own localisation evidence and controls (HPA: subcellular; general IF practice). Do not use an ICC-IF compartment call alone to validate an IHC tissue stain, whose reliability is uncertain (HPA: tissue IHC). |
Experiment evidence
IHC & IF images showing PDE4D staining
A01111-1 · IHCIHC analysis of PDE4D using anti-PDE4D antibody (A01111-1). PDE4D was detected in paraffin-embedded section of mouse lung tissue . Heat medi
A01111-1 · IHCIHC analysis of PDE4D using anti-PDE4D antibody (A01111-1). PDE4D was detected in paraffin-embedded section of human placenta tissue . Heat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000113448-PDE4D/tissue/cerebral+cortex#imid_12447105
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000113448-PDE4D/tissue/colon#imid_12447015
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000113448-PDE4D/tissue/liver#imid_12447024
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000113448-PDE4D/tissue/kidney#imid_12447017
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA045895; green = PDE4D, blue = nucleus, red = microtubules.
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA045895; green = PDE4D, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PDE4D IHC & IF
🧪Run colon first: glandular cells should stain strongly (HPA: High in colon glandular cells; UniProt Q08499: protein detected in colonic epithelial cells). HPA detects PDE4D in all 45 scored tissues, so there is no HPA-supported negative tissue; use no-primary and isotype controls, and compare adjacent nonglandular cells with the glandular cells without assuming they are PDE4D-negative (HPA: no negative tissue rows; standard IHC practice).
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: None in HPA: PDE4D is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PDE4D in HeLa, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), KOLF2.1J, with annotated localisation: Plasma membrane (supported), Cytosol (uncertain) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a concentration-matched rabbit IgG isotype control matched to the primary antibody’s clonality where known; use PDE4D-knockout material as a biological specificity control if available (caption: rabbit primary; standard IHC practice). With the caption’s biotin-based DAB detection, block endogenous peroxidase and assess endogenous biotin background in colon (caption: biotinylated secondary and DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A01111-1 tissue-IHC caption does not state the fixative (caption: fixative unreported). The caption uses citrate buffer at pH 6 for 20 minutes of heat retrieval, but does not establish that retrieval is required; the supplied evidence also does not establish whether frozen sections or IF would be easier (caption: heat retrieval; standard IHC practice). In colon, glandular signal should be interpreted against possible endogenous biotin background from the caption’s biotin-based detection (HPA: High in colon glandular cells; caption: biotinylated secondary; standard IHC practice).
HPA tissue IHC evidence for PDE4D
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: PDE4D is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced PDE4D IHC Tips
Troubleshoot PDE4D staining in paraffin sections by checking retrieval, compartment, background and scoring against the available tissue evidence.
What retrieval conditions should I try first for PDE4D in paraffin sections?
Start with heat-mediated citrate pH 6 antigen retrieval for 20 minutes on paraffin sections (datasheet A01111-1). The selected mouse lung image used those conditions before overnight incubation with 1 µg/mL catalog antibody at 4°C (datasheet A01111-1). If staining is weak, compare a small retrieval time series while keeping antibody concentration, detection and section thickness constant (standard IHC practice). Score signal alongside tissue morphology: damaged or detached sections make an apparent gain in staining difficult to interpret (standard IHC practice). Include a section processed without primary antibody to check whether retrieval increases detection background (standard IHC practice).
Could fixation explain weak or uneven PDE4D staining?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state its fixative (datasheet A01111-1). Record the fixative and processing history for every section before comparing PDE4D intensity across specimens (standard IHC practice). If material permits, process matched specimens under controlled fixation conditions, then stain them together using citrate pH 6 retrieval for 20 minutes (datasheet A01111-1; standard IHC practice). Compare morphology and staining in the same cell compartment, because differences in tissue preservation can confound intensity measurements (standard IHC practice). Neither the tissue staining profile nor the protein’s modifications establish a fixation effect (HPA tissue IHC; UniProt Q08499 modified residues).
Where should PDE4D staining appear, and how should I assess an unexpected pattern?
Assess cytoplasmic and membrane-associated staining, including possible apical accentuation in colonic glandular cells (HPA tissue IHC: ubiquitous cytoplasmic expression; UniProt Q08499 subcellular location). PDE4D lacks a transmembrane segment, so membrane-associated signal does not imply that the protein spans the membrane (UniProt Q08499 topology and subcellular location). Supported plasma-membrane localisation and uncertain cytosolic localisation in cell images offer context, but do not establish how every paraffin tissue must stain (HPA subcellular). Compare the suspected pattern with adjacent cells and a no-primary control under identical chromogenic settings (standard IHC practice). Treat isolated nuclear staining cautiously because the reported nucleoplasmic and nuclear-membrane locations are uncertain (HPA subcellular).
Can this stain distinguish PDE4D isoforms or phosphorylation states?
Do not assign an individual isoform from this stain without an antibody epitope map and isoform-specific validation (standard IHC interpretation). PDE4D has 12 listed isoforms, while its PDEase domain spans residues 386–715 in the listed sequence (UniProt Q08499 isoforms and domains). An antibody recognizing a shared region could stain several isoforms; recognition of a unique N-terminal region would require direct epitope evidence (UniProt Q08499 isoforms; standard immunostaining interpretation). Likewise, staining intensity cannot identify phosphorylation at residues such as serine 299 or 301 without modification-specific validation (UniProt Q08499 modified residues; standard immunostaining interpretation). Report the observed compartment and cell type before proposing an isoform mechanism (standard IHC practice).
How can I examine PDE4D by multiplex IF after seeing an IHC signal?
Treat IF as a separate assay and establish its fixation, antibody concentration and controls independently of the paraffin IHC image (datasheet A01111-1; standard IF practice). Multiplex PDE4D with a marker identifying the expected cell population, such as glandular cells in colon, and inspect colocalisation by compartment rather than overlapping colours alone (HPA tissue IHC: high in colon glandular cells; standard IF practice). Choose a fluorophore channel after measuring tissue autofluorescence and include single-stain controls for spectral bleed-through (standard IF practice). Optimise permeabilisation for access to the mapped epitope: a cytosolic-facing epitope may require it, whereas an accessible extracellular epitope may not (UniProt Q08499 topology; standard IF practice). The antibody’s epitope orientation is unspecified here (datasheet A01111-1).
How do I separate PDE4D staining from chromogenic background?
Run a no-primary control through the complete secondary and detection sequence to identify background unrelated to primary binding (standard IHC practice). The selected image used 10% goat serum, biotinylated goat anti-rabbit secondary, a streptavidin–biotin detection complex and DAB (datasheet A01111-1). For excess diffuse colour, assess blocking and washing, endogenous peroxidase activity, and background associated with biotin-based detection on matched sections (standard IHC practice). Keep development time and imaging settings consistent while changing only one variable at a time (standard IHC practice). Judge candidate PDE4D signal against cell shape and compartment, since the tissue profile describes widespread cytoplasmic staining (HPA tissue IHC).
What is a defensible way to quantify PDE4D IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and cell population before scoring, then use an H-score based on the percentage of cells at each intensity or report percentage positive cells (standard IHC quantification). If counting discrete positive cells, express density per mm² of evaluable tissue rather than per image (standard IHC quantification). Normalise comparisons to the same cell population, tissue area, counterstain quality and chromogen development conditions (standard IHC practice). Record cytoplasmic and membrane-associated staining separately when both are visible, since PDE4D has reported cytoplasmic and membrane-associated locations (HPA tissue IHC; UniProt Q08499 subcellular location). Set thresholds with controls and apply them unchanged across the comparison set (standard IHC quantification).
What makes an apparent PDE4D-positive cell convincing rather than artefactual?
Prioritise reproducible staining in intact cells with a plausible cytoplasmic or membrane-associated pattern (HPA tissue IHC; UniProt Q08499 subcellular location). High staining in colon glandular cells is a useful tissue reference, but the HPA tissue IHC reliability is rated uncertain (HPA tissue IHC: high in colon glandular cells; reliability uncertain). Treat colour restricted to section edges, necrotic areas or visibly damaged tissue as suspect, and compare it with a no-primary control (standard IHC practice). Check whether an unexpected cell type reflects identifiable morphology before assigning biological meaning (standard IHC interpretation). Residual endogenous peroxidase can produce DAB colour, so control-section colour cannot establish PDE4D expression (standard IHC practice).
Boster reagents
Best PDE4D / 3',5'-cyclic-AMP phosphodiesterase 4D IHC Antibodies
A01111-1 has IHC images from paraffin sections of mouse lung, human placenta and rat lung (catalog image captions). ICC is listed as an application; no IF image is supplied (catalog applications and images).
Real IHC data
Anti-PDE4D Antibody ®
Cat # A01111-1
A01111-1 will render with its mouse lung IHC figure (card image caption). Its catalog also shows paraffin-section IHC in human placenta and rat lung and lists human, mouse and rat reactivity plus ICC (catalog image captions and reactivity/application lists).
Which to pick: For tissue IHC, choose A01111-1: its own caption documents citrate retrieval at pH 6 for 20 minutes and antibody at 1 μg/ml on a paraffin mouse lung section (card image caption). For IF/ICC, A01111-1 lists ICC and 0.5–1 μg/ml, but supplies no IF image; for cross-species IHC, its captions show human, mouse and rat tissues (catalog applications, dilution and image captions). Clonality and fixative are unreported (catalog clone field and image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q08499 (PDE4D_HUMAN, 3',5'-cyclic-AMP phosphodiesterase 4D).
- Human Protein Atlas. PDE4D tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. PDE4D subcellular location (ICC-IF): Mainly localized to the plasma membrane and cytosol. In addition localized to the nucleoplasm, nuclear membrane and primary cilium..
- Human Protein Atlas. PDE4D antibody validation summary (1 antibodies).
- ATP8B1 Deficiency Causes Phosphodiesterase 4-Mediated Glucagon Resistance and Impaired Gluconeogenesis in Mouse and Human Liver. Liver international : official journal of the International Association for the Study of the Liver 2025 — PMC12375944.
- Phosphodiesterase 4D promotes angiotensin II-induced hypertension in mice via smooth muscle cell contraction. Communications biology 2022 — PMC8776755.
- Phosphodiesterase PDE4D Is Decreased in Frontal Cortex of Aged Rats and Positively Correlated With Working Memory Performance and Inversely Correlated With PKA Phosphorylation of Tau. Frontiers in aging neuroscience 2020 — PMC7655962.
- High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma. Journal of Cancer 2019 — PMC6856734.
- PubMed PMID:8413254 — UniProt-cited evidence.
- PubMed PMID:8797812 — UniProt-cited evidence.
- PubMed PMID:8125310 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PDE4D (3',5'-cyclic-AMP phosphodiesterase 4D). Expected localisation Ubiquitous cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A01111-1). Validated IHC antibody: A01111-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse lung tissue; fixative not specified (datasheet A01111-1); 2. Fixation: Image fixative and duration unreported (datasheet A01111-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A01111-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01111-1); 8. Primary antibody: Rabbit anti-PDE4D, 0.5-1μg/ml (datasheet A01111-1); 9. Primary incubation: Overnight at 4 °C (datasheet A01111-1). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining has only medium consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 12 isoforms; N-terminal epitopes may vary; no TM span (UniProt); Regulation: Tissue-enhanced RNA: marrow, muscle (HPA tissue RNA). Evidence: UniProt Q08499, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the plasma membrane and cytosol. In addition…, Datasheet A01111-1, PMC12375944, PMC8776755. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PDE4D/immunohistochemistry-ihc-guide.